Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 480

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Loss of Heterozygosity for Chromosomes 1p and 16q Is an Adverse Prognostic Factor in Favorable-Histology Wilms Tumor: A Report From the National Wilms Tumor Study Group

Grundy, Paul E., Breslow, Norman E., Li, Sierra, Perlman, Elizabeth, Beckwith, J. Bruce, Ritchey, Michael L., Shamberger, Robert C., Haase, Gerald M., D'Angio, Giulio J., Donaldson, Milton, Coppes, Max J., Malogolowkin, Marcio, Shearer, Patricia, Thomas, Patrick R.M., Macklis, Roger, Tomlinson, Gail, Huff, Vicki, Green, Daniel M.·2005·Journal of Clinical Oncology

Abstract

Purpose: To determine if tumor-specific loss of heterozygosity (LOH) for chromosomes 1p or 16q is associated with a poorer prognosis for children with favorable-histology (FH) Wilms tumor entered on the fifth National Wilms Tumor Study (NWTS-5). Patients and Methods: Between August 1995 and June 2002, 2,021 previously untreated children with FH or anaplastic Wilms tumor, clear-cell sarcoma of the kidney (CCSK) or malignant rhabdoid tumor of the kidney (RTK), were treated with stage- and histology-specific therapy. Their tumors were assayed for LOH for polymorphic DNA markers on chromosomes 1p and 16q. Results: LOH for 1p or 16q was rarely observed in CCSK (n = 90) or RTK (n = 22). The relative risk (RR) of relapse for patients with FH stage I to IV tumors with LOH, stratified by stage, was 1.56 for LOH 1p (P = .01) and 1.49 for LOH 16q (P = .01), whereas the RR of death was 1.84 (P = .03) and 1.44 (P = .15), respectively. When the effects of LOH for both regions were considered jointly among patients with stage I to II FH disease, the risks of relapse and death were increased for LOH 1p only (RR = 2.2, P = .02 for relapse; RR = 4.0, P = .02 for death), for LOH 16q only (RR = 1.9, P = .01 and RR = 1.4, P = .60) and for LOH for both regions (RR = 2.9, P = .001 and RR = 4.3, P = .01) in comparison with patients with LOH at neither locus. The risks of relapse and death for patients with stage III to IV FH tumors were increased only with LOH for both regions (RR = 2.4, P = .01 and RR = 2.7, P = .04). Conclusion: Tumor-specific LOH for both chromosomes 1p and 16q identifies a subset of FH Wilms tumor patients who have a significantly increased risk of relapse and death. LOH for these chromosomal regions can now be used as an independent prognostic factor together with disease stage to target intensity of treatment to risk of treatment failure.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2005.01.2799

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 480

Metadata

Authors
Grundy, P. E., Breslow, N. E., Li, S., Perlman, E., Beckwith, J. B., Ritchey, M. L., Shamberger, R. C., Haase, G. M., D'Angio, G. J., Donaldson, M., Coppes, M. J., Malogolowkin, M., Shearer, P., Thomas, P. R. M., Macklis, R., Tomlinson, G., Huff, V., & Green, D. M.
Venue
Journal of Clinical Oncology
Published
2005-10-10
Volume
23
Issue
29
Pages
7312-7321
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2171862017
Cited by
480
References
17
FWCI
7.49
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Loss of Heterozygosity for Chromosomes 1p and 16q Is an Adverse Prognostic Factor in Favorable-Histology Wilms Tumor: A Report From the National Wilms Tumor Study Group. https://app.cochat.ai/papers/10.1200/jco.2005.01.2799
The paper
Grundy, P. E., Breslow, N. E., Li, S., Perlman, E., Beckwith, J. B., Ritchey, M. L., Shamberger, R. C., Haase, G. M., D'Angio, G. J., Donaldson, M., Coppes, M. J., Malogolowkin, M., Shearer, P., Thomas, P. R. M., Macklis, R., Tomlinson, G., Huff, V., & Green, D. M. (2005). Loss of Heterozygosity for Chromosomes 1p and 16q Is an Adverse Prognostic Factor in Favorable-Histology Wilms Tumor: A Report From the National Wilms Tumor Study Group. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.01.2799

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.